bimagrumab + semaglutide Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity The Evolving Landscape of Anti-Obesity
Description
As the use of GLP-1 receptor agonists continues to expand for the treatment of type 2 diabetes and obesity, questions have emerged about their potential gastrointestinal side effectsparticularly gastroesophageal reflux disease (GERD)
how_to_use: Injected subcutaneously into the abdomen, thigh, or upper arm
It involves more than just diet and exercise
For clinicians and patients, this is a moment of transition
Affordable Telehealth Weight Loss Solutions from Sapphire RX
